Shares of Insys Therapeutics Inc (NASDAQ:INSY) have been assigned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $6.35.
Several research firms have weighed in on INSY. Janney Montgomery Scott cut Insys Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, May 14th. ValuEngine cut Insys Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research raised Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 9th. Piper Jaffray Companies set a $4.00 price target on Insys Therapeutics and gave the company a “sell” rating in a report on Friday, March 8th. Finally, Royal Bank of Canada lowered their price target on Insys Therapeutics from $9.00 to $7.00 and set an “outperform” rating on the stock in a report on Friday, March 8th.
Shares of NASDAQ:INSY traded down $0.05 on Thursday, hitting $0.91. The company’s stock had a trading volume of 916,282 shares, compared to its average volume of 1,136,423. Insys Therapeutics has a 1 year low of $0.82 and a 1 year high of $11.65. The stock has a market cap of $71.45 million, a P/E ratio of -0.65 and a beta of 2.43.
Insys Therapeutics (NASDAQ:INSY) last released its quarterly earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.33). Insys Therapeutics had a negative net margin of 346.61% and a negative return on equity of 1,430.52%. The business had revenue of $7.63 million during the quarter, compared to analysts’ expectations of $14.95 million. During the same period in the previous year, the business earned ($0.19) EPS. The business’s revenue was down 68.1% on a year-over-year basis. As a group, equities analysts expect that Insys Therapeutics will post -1.55 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of Insys Therapeutics by 2.8% during the 3rd quarter. BlackRock Inc. now owns 2,710,787 shares of the specialty pharmaceutical company’s stock valued at $27,325,000 after buying an additional 73,282 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Insys Therapeutics during the 3rd quarter valued at about $113,000. Two Sigma Advisers LP purchased a new position in shares of Insys Therapeutics during the 4th quarter valued at about $53,000. Millennium Management LLC raised its holdings in shares of Insys Therapeutics by 88.7% during the 4th quarter. Millennium Management LLC now owns 545,487 shares of the specialty pharmaceutical company’s stock valued at $1,909,000 after buying an additional 256,474 shares in the last quarter. Finally, ETF Managers Group LLC purchased a new position in shares of Insys Therapeutics during the 4th quarter valued at about $5,076,000. 13.92% of the stock is currently owned by institutional investors.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc, a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Featured Story: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.